Stock ACXP ACURX PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Acurx Pharmaceuticals, Inc.

Equities

ACXP

US00510M1045

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
2.51 USD -.--% Intraday chart for Acurx Pharmaceuticals, Inc. -.--% -34.46%
May. 15 Acurx Announces Successful FDA End-of-Phase 2 Meeting and Phase 3 Readiness for Ibezapolstat in the Treatment of C. difficile Infection CI
May. 15 Transcript : Acurx Pharmaceuticals, Inc., Q1 2024 Earnings Call, May 15, 2024

Valuation

Fiscal Period: December 2021 2022 2023 2024 2025 2026
Capitalization 1 44.15 46.14 52.73 39.72 - -
Enterprise Value (EV) 1 44.15 46.14 52.73 39.72 39.72 39.72
P/E ratio -2.9 x -3.55 x -3.33 x -2.44 x -1.58 x -1.16 x
Yield - - - - - -
Capitalization / Revenue - - - - - 2.48 x
EV / Revenue - - - - - 2.48 x
EV / EBITDA - - - - - -
EV / FCF -3,483,532 x - - - - -
FCF Yield -0% - - - - -
Price to Book - - - - - -
Nbr of stocks (in thousands) 10,216 11,593 13,768 15,823 - -
Reference price 2 4.321 3.980 3.830 2.510 2.510 2.510
Announcement Date 3/16/22 3/15/23 3/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net sales 1 - - - - - - 16.03
EBITDA - - - - - - -
EBIT 1 - -12.81 -12.09 -14.58 -17.35 -25.77 -16.74
Operating Margin - - - - - - -104.41%
Earnings before Tax (EBT) 1 - -12.75 -12.09 -14.58 -17.35 -28.16 -40.21
Net income 1 -4.6 -12.75 -12.09 -14.58 -17.35 -25.77 -16.74
Net margin - - - - - - -104.41%
EPS 2 -0.7500 -1.490 -1.120 -1.150 -1.030 -1.590 -2.155
Free Cash Flow - -12.67 - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 4/5/21 3/16/22 3/15/23 3/15/24 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - - - -
EBITDA - - - - - - - - - - - - -
EBIT 1 -2.627 -2.67 - -3.542 -3.261 -2.903 -3.445 -3.115 -5.115 -4.378 -3.85 -3.775 -5.35
Operating Margin - - - - - - - - - - - - -
Earnings before Tax (EBT) 1 -2.627 -2.67 - -3.542 -3.261 -2.903 -3.445 -3.115 -5.115 -4.378 -3.85 -3.775 -5.35
Net income 1 -2.627 -2.67 -2.621 -3.542 -3.261 -2.903 -3.445 -3.115 -5.115 -4.378 -3.85 -3.775 -5.35
Net margin - - - - - - - - - - - - -
EPS 2 -0.2200 -0.2600 -0.2600 -0.3200 -0.2800 -0.2500 -0.2800 -0.2400 -0.3800 -0.2800 -0.2200 -0.2150 -0.3150
Dividend per Share - - - - - - - - - - - - -
Announcement Date 3/16/22 5/10/22 8/12/22 11/10/22 3/15/23 5/12/23 8/11/23 11/13/23 3/15/24 5/14/24 - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) - - - - - - -
Free Cash Flow - -12.7 - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex - - - - - - -
Capex / Sales - - - - - - -
Announcement Date 4/5/21 3/16/22 3/15/23 3/15/24 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
2
Last Close Price
2.51 USD
Average target price
11.45 USD
Spread / Average Target
+356.18%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ACURX PHARMACEUTICALS, INC. Stock Acurx Pharmaceuticals, Inc.
-34.46% 39.72M
MODERNA, INC. Stock Moderna, Inc.
+43.36% 54.63B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-5.31% 39.92B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+14.75% 26.86B
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-22.45% 18.78B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.12% 12.21B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+0.04% 12.16B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.04% 11.94B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-11.83% 10.74B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ACXP Stock
  4. Financials Acurx Pharmaceuticals, Inc.